IQVIA Institute for Human Data Science

IQVIA Institute's on-demand webinar reveals key findings from our report on Rethinking Clinical Trial Country Prioritization. This independent analysis examines trends in enrollment, trial characteristics, and country utilization over the past five years. Highlights include: - Expanding the footprint of #clinicaltrials on a global scale - Addressing capacity challenges in key therapeutic areas - Improving #patientrecruitment and retention strategies Watch now: https://bit.ly/4f7RJ71.

What will it take to strengthen Europe as a global center for oncology trials? Elizabeth Theogaraj, PhD., Global Regulatory Lead at Roche, believes it comes down to collaboration. She highlights that bringing together all stakeholders—sites, vendors, industry, and local healthcare infrastructure—is essential to moving the needle. Co-creation is the key to making real progress, particularly in oncology, where Europe's role can grow even stronger on the global stage. Hear more of her insights on how collaboration can drive Europe's leadership in oncology trials: https://bit.ly/4hbMFjS.

The latest insight brief from the IQVIA Institute, Accelerating Health Equity: Challenges and Opportunities, addresses the need for clear definitions when measuring health equity. Ill-served groups vary across different geographies and income levels, making it essential to tailor approaches for high, middle, and low-income countries. Establishing meaningful metrics for impact and defining reach beyond simple social media impressions are also vital steps in advancing health equity, diversity and inclusion. As global health equity initiatives grow, refining these measurements is key to creating impactful, sustainable change: https://bit.ly/3A9vYVy.

What health policy priorities should the next U.S. administration focus on? As the 2024 U.S. elections approach, healthcare remains a critical topic for voters and policymakers alike. IQVIA Institute invites you to an on-demand webinar featuring top health policy researchers and leaders who will discuss the key issues that could shape the next administration's agenda. Join experts Lanhee Chen, Patricia Kelmar, Richard Frank, and others as they explore the potential health policy changes and challenges. Watch the insightful conversation: https://bit.ly/406pMbz.

Which #Medicare Part D patients are driving the demand for new-to-brand prescriptions? Exhibit 3 in the CMS Prescription Drug Negotiations report sheds light on the New-to-Brand Rx (NBRx) share among Medicare Part D patients. Over 50% of those using selected drugs receive them through Medicare Part D, with about 40% benefiting from Low-Income Subsidies (LIS). These trends reveal the important role LIS patients play in driving demand while maintaining low out-of-pocket costs. Download the full report: https://bit.ly/3NsOOdC.

IQVIA Institute just released a report on the CMS Prescription Drug Negotiations, examining the impact of the Inflation Reduction Act (IRA) on Medicare prescription drug prices. One of the IRA’s primary goals is to improve Medicare affordability and accessibility, but the actual savings for beneficiaries may be limited. The report highlights key provisions such as the $2,000 annual cap on out-of-pocket costs and insulin priced at $35/month. It also explores the newly introduced federal negotiations with drug manufacturers, aimed at reducing the cost of high-expenditure brand-name drugs under Medicare Part B and Part D. However, the analysis shows that government price negotiations may not consistently reduce patient cost sharing, with many Medicare enrollees seeing little to no financial benefit. Our report is essential for anyone following the evolving landscape of Medicare. https://bit.ly/3zJdWJR #Medicare #PharmaSpending #HealthcarePolicy

Every clinical trial is unique in its characteristics and site requirements; however, examining trials in aggregate provides valuable insights. Our report on Rethinking Clinical Trial Country Prioritization identifies four key trial segments that map to distinct country capabilities. These segments include: 🏥Clinical Focus 🏥Clinical Efficiency 🏥Scientific Emphasis 🏥Medical Maturity These segments align to four basic trial types based on trial intensity and patient volume needs. By matching these trial types to the infrastructure and operational capabilities of different countries, unique profiles emerge, offering a strategic approach to selecting the most suitable trial locations. Understanding this alignment is critical for optimizing trial execution and improving outcomes globally: https://bit.ly/3TYeL8w. #ClinicalTrials #GlobalHealth #Europe

Missed the live discussion? You can now watch it on-demand: Health Policy Forum: Policy Priorities for the Next U.S. Administration. Featuring top health policy researchers and leaders, this session dives into critical healthcare topics that will shape the 2024 U.S. elections. From healthcare affordability to Medicare reform, this insightful forum addresses the key policy challenges and opportunities the next administration will face. Watch the full discussion here: https://bit.ly/3NitUgY. #HealthPolicy #PublicHealth

Missed the Pre-ESMO Symposium? Catch up on José Luis García, MD, Ph.D., Senior Medical Strategy Director at IQVIA Oncology Center of Excellence, as he discusses why Europe is uniquely positioned to lead oncology trials, with established networks and strong national health systems. 🔗 Watch on-demand now: https://bit.ly/3YcX5s2. #OncologyTrials #ClinicalTrials ClinicalResearch

Radioligand therapy availability varies across Europe, with Spain and Germany leading in treatment capacity, offering more than 55 treatment slots per 100,000 people. However, France and Italy have much lower capacity, highlighting the need for increased readiness. Scaling radioligand therapy across Europe will require addressing these critical factors to ensure better access for patients. https://bit.ly/47XmQjq #RadioligandTherapy #Oncology #GlobalHealth